Results 61 to 70 of about 3,781 (191)

Delamanid and its Role in Drug-Resistant Tuberculosis

, 2017
The World Health Organisation estimates that one-third of the world's population are currently infected with Tuberculosis bacillus, 10% of whom will develop the disease at some point in their lifetime.
Supratik Das, Vijay Kumar Sehgal
core   +1 more source

Protein Target Highlights in CASP16: Insights From the Structure Providers

Proteins: Structure, Function, and Bioinformatics, Volume 94, Issue 1, Page 25-50, January 2026.
ABSTRACT This article presents an in‐depth analysis of selected CASP16 targets, with a focus on their biological and functional significance. The authors highlight the most relevant features of the target proteins and discuss how well these were reproduced in the submitted predictions.
Leila T. Alexander, Océane M. Follonier, Andriy Kryshtafovych, Kim Abesamis, Sabrina Bibi‐Triki, Henry G. Box, Cécile Breyton, Françoise Bringel, Loic Carrique, Alessio d'Acapito, Gang Dong, Rebecca DuBois, Deborah Fass, Juliana Martinez Fiesco, Daniel R. Fox, Jonathan M. Grimes, Rhys Grinter, Matthew Jenkins, Roman Kamyshinsky, Jeremy R. Keown, Gerald Lackner, Michael Lammers, Shiheng Liu, Andrew L. Lovering, Tomas Malinauskas, Benoît Masquida, Gottfried J. Palm, Christian Siebold, Tiantian Su, Ping Zhang, Z. Hong Zhou, Krzysztof Fidelis, Maya Topf, John Moult, Torsten Schwede   +34 more
wiley   +1 more source

Recent Progress in the Discovery and Development of 2-Nitroimidazooxazines and 6-Nitroimidazooxazoles to Treat Tuberculosis and Neglected Tropical Diseases

Molecules, 2020
Nitroimidazole drugs have a long history as therapeutic agents to treat bacterial and parasitic diseases. The discovery in 1989 of a bicyclic nitroimidazole lead, displaying in vitro and in vivo antitubercular activity, spurred intensive exploration of ...
Hollis D. Showalter
doaj   +1 more source

Extensive Lymphadenopathy in an HIV‐Negative Patient With Multidrug‐Resistant Tuberculosis

Respirology Case Reports, Volume 14, Issue 1, January 2026.
Extensive lymphadenopathy is uncommon in HIV‐negative patients with tuberculosis. This clinical image highlights the striking CT appearance of extensive extrapulmonary lymph node involvement in symptomatic multidrug‐resistant tuberculosis, even in the absence of HIV infection. ABSTRACT Tuberculous lymphadenitis is generally more severe in patients with
Tomoyuki Araya, Toshiyuki Kita, Kazuhiko Iwasaki, Takayuki Higashi, Ryo Hara, Hazuki Takato   +5 more
wiley   +1 more source

Identification of Patients Who Could Benefit from Bedaquiline or Delamanid: a Multisite MDR-TB Cohort Study

, 2016
The World Health Organization recommends adding bedaquiline or delamanid to multidrug-resistant tuberculosis (MDR-TB) regimens for which four effective drugs are not available, and delamanid for patients at high risk of poor ...
Telnov, A, Hayrapetyan, A, Hewison, C, Khamraev, A, Bonnet, M, Themba, D, Kimenye, K, Bastard, M, Varaine, F, Khurkhumal, S, du Cros, P, Sanchez-Padilla, E   +11 more
core   +1 more source

Population Pharmacokinetics of Delamanid and its Main Metabolite DM-6705 in Drug-Resistant Tuberculosis Patients Receiving Delamanid Alone or Coadministered with Bedaquiline

, 2022
BACKGROUND AND OBJECTIVE: Delamanid is a nitroimidazole, a novel class of drug for treating tuberculosis, and is primarily metabolized by albumin into the metabolite DM-6705.
Diacon, A.H., Svensson, E.M., Maartens, G., Dooley, Kelly E,, De Los Rios, Jorge, Diacon, Andreas H., Dooley, Kelly E., Dooley, Kelly E, Karlsson, Mats,, Diacon, Andreas H,, Upton, Caryn M, Shenje, J., Rios, J. De Los, Wiesner, Lubbe, Karlsson, M.O., Maartens, Gary, Upton, C.M., Tanneau, Lénaïg,, Svensson, Elin, Karlsson, Mats, Tanneau, L., Maartens, Gary,, Upton, Caryn M,, Upton, Caryn M., Shenje, Justin, Wiesner, L., De los rios, Jorge,, Wiesner, Lubbe,, Tanneau, Lénaïg, Diacon, Andreas H, Shenje, Justin,, Svensson, Elin,, Svensson, Elin M., Karlsson, Mats O., Kelly E. Dooley, Mats O. Karlsson, Caryn M. Upton, Justin Shenje, Lénaïg Tanneau, Elin M. Svensson, Lubbe Wiesner, Gary Maartens, Andreas H. Diacon, Jorge De Los Rios   +43 more
core   +1 more source

Combating Drug‐Resistant Tuberculosis: Advancements in Diagnostics and Therapeutics

Pulmonary Medicine, Volume 2026, Issue 1, 2026.
The increasing prevalence of multidrug‐resistant (MDR) and extensively drug‐resistant (XDR)Mycobacterium tuberculosis has emerged as a major global health concern. Advanced molecular diagnostics, including rapid assays, have improved resistance detection; however, resource‐limited settings remain underserved. Nanotechnology‐based drug delivery systems,
Silvi Gautam, Jahanvi Saini, Shabaaz Begum Jameel Pasha, Divakar Sharma, Divya Venugopal, Semonti Nandi   +5 more
wiley   +1 more source

Chemical structure of clinically approved anti-TB drugs bedaquiline (1) and delamanid (2).

, 2019
Chemical structure of clinically approved anti-TB drugs bedaquiline (1) and delamanid (2).
Hassan H. Abdallah (1936783), Mahesh Attimarad (4353310), Anroop B. Nair (6796820), Subhrajyoti Bhandary (2617587), Sandeep Chandrashekharappa (4353304), Nagaraja Sreeharsha (6796823), Shinu Pottathil (6796829), Melendhran Pillay (480710), Mohamed A. Morsy (6796826), Rashmi Venugopala (6796832), Koleka Mlisana (72866), Fawzi M. Mahomoodally (6262904), Bandar E. Aldhubiab (4353307), Katharigatta Narayanaswamy Venugopala (6796817), Deepak Chopra (328612), Bharti Odhav (4353301)   +15 more
core   +1 more source

New drugs in the treatment of drug-resistant tuberculosis in children. Experience with the use of delamanid in combination with bedaquiline

Journal of Global Antimicrobial Resistance
OBJECTIVE: To determine the safety and effectiveness of delamanid in combination with bedaquiline in children for the treatment of multidrug-resistant tuberculosis. MATERIALS-METHODS: In 2023-2024, 18 children aged 3 to 17 years with MDR-TB were treated.
Ekaterina Sokolskaya, Nadezhda Klevno, Anastasiya Samoylova, Alexey Kazakov, Anastasiya Gaida   +4 more
doaj   +1 more source

Tiny Lungs, Big Challenge: The Treatment Landscape of Pediatric Tuberculosis

Pulmonary Medicine, Volume 2026, Issue 1, 2026.
Tuberculosis was a lethal disease until the early 1950s, when the first anti‐TB drugs were discovered. These drugs saved many lives until bacteria developed resistance in the 1980s. As a result, TB has re‐emerged as a global health challenge, affecting both drug‐susceptible and drug‐resistant cases.
Lucia N. Dumeni, Pradeep Kumar, Yahya E. Choonara, Semonti Nandi   +3 more
wiley   +1 more source